COMMENTARY: Approved Hormonal Treatments for HSDD: An Unmet Medical Need

In the context of increased regulatory scrutiny, increasing off-label use of testosterone, formulation and dosing issues, increased patient awareness of FSD and HSDD, and overall favorable physician sentiment, the completion of the LibiGel® clinical development program and an FDA approval will meet the demand for the first safe and effective FDA-approved treatment of HSDD in postmenopausal women. Snabes MC, and Simes SM. Approved hormonal treatments for HSDD: An unmet medical need. J Sex Med 2009;6:1846-1849.